Bruker Announces Successful Customer Installations of First Two Compact 1.0 GHz NMR Systems to Advance Structural Biology
03 February 2023 - 11:00PM
Business Wire
Novel compact, single-story 4 Kelvin 1.0 GHz
NMR systems already accepted at RIKEN, Japan and University of
Barcelona, Spain in late 2022 ahead of schedule
Bruker today announced successful customer installations of two
novel, compact 1.0 GHz NMR spectrometers for advanced structural
and molecular biology applications well ahead of original schedules
in late 2022. Both new Ascend Evo 1.0 GHz NMR systems
operate at 4.2 Kelvin without subcooling below liquid Helium
temperatures, and as a result have ~65% lower liquid Helium
consumption than previous 1.0 GHz 2 Kelvin, two-story magnets.
These new 1.0 GHz NMR magnets also have significantly reduced
footprint, weight, and ceiling height requirements and fit into
most single-story laboratories. The compact systems are easier to
manufacture, site and install, thus allowing acceptance in shorter
timeframes.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230203005036/en/
Dr. Ichio Shimada, Team Leader at RIKEN
Center for Biosystems Dynamics Research in Yokohama, Japan (Photo:
Business Wire)
Both compact ultra-high field NMR systems are generating
excellent scientific data for functional structural and molecular
biology, as well as for phenomics clinical research. This allows
scientists to dive deeper into the structural details, binding and
dynamics of protein structures and complexes for fundamental cell
biology and pathobiology research. The RIKEN Center for Biosystems
Dynamics Research in Yokohama, Japan was the first to receive the
Ascend Evo 1.0 GHz NMR system, which was successfully installed and
accepted in less than two months. The RIKEN team under Dr. Ichio
Shimada will use GHz NMR to study dynamic structures of
biomolecules in solution and to investigate the relationships
between dynamic structures and biological function or
pathobiology.
Prof. Ichio Shimada stated “I’m very satisfied about the smooth
delivery and installation of this brand new Ascend Evo 1.0 GHz
spectrometer in late 2022. We started producing first NMR research
results already a few weeks after the successful commissioning.
This ultra-high field GHz-class NMR spectrometer delivers new
insights for our GPCR and RNA research, which is newly launched,
with excellent resolution and highly sensitive direct detection
capabilities for 15N and 13C. This will support and strengthen our
research in structural biology with a particular focus on
dynamics.”
In 2022, the Spanish Singular Scientific and Technical
Infrastructures (ICTS) high-field NMR network with nodes in
Barcelona, Madrid and Bilbao, purchased two 1.0 GHz instruments to
be sited in Barcelona and Bilbao. These instruments will be open
for competitive access and will pave the way for a new structural
biology hub in Spain. The Ascend Evo 1.0 GHz NMR instrument in
Barcelona was successfully installed in less than 6 weeks and is
already generating exceptional data. The second Spanish 1.0 GHz
system is expected to be delivered to CIC bioGUNE in Bilbao in the
summer of 2023.
Professor Miquel Pons Valles, Group Leader of the BioNMR Group
at Universitat de Barcelona and his team use biophysical methods,
especially NMR, as well as chemical biology, molecular biology, and
computations to study proteins in regulatory processes, where
dynamics is essential for function. The Ascend Evo 1.0 GHz NMR will
also advance their research on functionally very important
intrinsically disordered proteins (IDPs).
Dr. Falko Busse, President of the Bruker BioSpin Group,
commented: "We are excited to announce the remarkably rapid
delivery and customer acceptance of two 1.0 GHz NMR systems. These
low-maintenance, compact NMRs with lower helium consumption can
bring the power of GHz NMR to many more laboratories.”
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high performance scientific instruments and high
value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. For more information, please visit:
www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230203005036/en/
Investor Contact: Justin Ward Sr. Director, Investor
Relations & Corporate Development Bruker Corporation T: +1
(978) 663-3660 x1479 E: Investor.Relations@bruker.com
Media Contact: Markus Ziegler Sr. Director and Head of
Group Marketing Bruker BioSpin T: +49 172 3733531 E:
pr@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024